Gastric cancer is a form of malignancy originating in the stomach lining cells. Therefore, it can also be referred to as stomach cancer. It starts in the innermost layer of the stomach and can then invade other layers of the stomach wall as it progresses. The types of gastric cancer are adenocarcinoma, lymphoma, gastrointestinal stromal tumors (GISTs), and carcinoid tumors, among others.
Established on July 1875, this multinational conglomerate has its headquarters in Tokyo, Japan. It was founded by Tanaka Hisashige and Ichisuke Fujioka. Toshiba is involved in various sectors, such as information technology, semiconductors, and healthcare.
In context to gastric cancer, it develops and manufactures medical imaging and diagnostic equipment, including endoscopy systems, ultrasound machines, and computed tomography (CT) scanners. These technologies are essential for the detection, diagnosis, and monitoring of various medical conditions, including gastric cancer.
Established in 1888, the company has its headquarters set up in Chicago, Illinois, United States. Wallace Calvin Abbott is the founding father of Abbott Laboratories. It is involved in the development, manufacturing, and distribution of a wide range of healthcare products, including pharmaceuticals, medical devices, diagnostics, nutrition products, and laboratory equipment.
The company has been playing a significant role in gastric cancer diagnostics. It produces a variety of diagnostic tests, including blood tests and tissue-based assays that can help in the detection, diagnosis, and monitoring of gastric cancer. These tests may detect specific biomarkers or proteins associated with gastric cancer, aiding in early diagnosis and treatment planning.
Headquartered in Kalamazoo, Michigan, United States, the company was established in 1941. It specializes in the development, manufacturing, and distribution of a wide range of medical devices and equipment.
Stryker offers a range of surgical instruments and equipment used in minimally invasive and open surgical procedures related to gastric cancer, such as gastrectomy or lymph node dissection. The company’s inventions help healthcare providers perform surgeries more effectively, reduce patient recovery times, and improve the overall quality of care delivered to individuals with gastric cancer.
Headquartered in Melsungen, Germany, the company was formed in 1839. It specializes in the development, manufacturing, and distribution of a wide range of healthcare products and services, with a particular emphasis on medical devices, pharmaceuticals, and hospital care.
Braun provides IV therapy products, including IV solutions, catheters, and infusion pumps. These are essential for the administration of chemotherapy and supportive care for gastric cancer patients undergoing treatment. It also provides IV therapy products, including IV solutions, catheters, and infusion pumps. These are essential for the administration of chemotherapy and supportive care for gastric cancer patients undergoing treatment.
Headquartered in Indianapolis, Indiana, United States, the company was founded in 1876. It is known for its extensive portfolio of pharmaceutical products, which include medications for a wide range of medical conditions.
Eli Lilly & Company has a substantial presence in the field of oncology and has developed several medications for the treatment of various cancers including gastric cancer. One such drug is Ramucirumab (brand name Cyramza), which is approved for the treatment of advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. It is often used in combination with other chemotherapy drugs.
In the landscape of gastric cancer treatment and diagnostics, several top companies play crucial roles, each contributing to different aspects of patient care. These companies, such as Eli Lilly and Company, B. Braun Melsungen AG, Abbott Laboratories, and Toshiba, offer a wide range of products and services that support the detection, diagnosis, and treatment of gastric cancer. Whether through the development of pharmaceuticals, medical devices, diagnostic tests, or healthcare technology, these industry leaders are collectively working to advance the understanding and management of gastric cancer. Their combined efforts contribute to improved outcomes, early detection, and enhanced patient care in the fight against this challenging disease.
How we can help?